Heartflow (NASDAQ:HTFL) Insider Sells $1,590,093.12 in Stock

Heartflow, Inc. (NASDAQ:HTFL) insider Campbell Rogers sold 64,533 shares of the business’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $24.64, for a total value of $1,590,093.12. Following the completion of the transaction, the insider directly owned 81,002 shares of the company’s stock, valued at approximately $1,995,889.28. This trade represents a 44.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Campbell Rogers also recently made the following trade(s):

• On Thursday, March 19th, Campbell Rogers sold 64,533 shares of Heartflow stock. The shares were sold at an average price of $25.69, for a total value of $1,657,852.77.
• On Thursday, February 12th, Campbell Rogers sold 65,153 shares of Heartflow stock. The stock was sold at an average price of $24.49, for a total value of $1,595,596.97.

Heartflow Stock Performance

NASDAQ:HTFL remained flat at $24.83 on Friday. 1,818,146 shares of the company’s stock were exchanged, compared to its average volume of 1,704,032. Heartflow, Inc. has a 52 week low of $20.13 and a 52 week high of $41.22. The stock has a market cap of $2.13 billion and a P/E ratio of -12.48. The stock’s 50-day simple moving average is $25.12 and its two-hundred day simple moving average is $29.90.

Analysts Set New Price Targets

A number of analysts recently issued reports on HTFL shares. Canaccord Genuity Group raised their target price on shares of Heartflow from $40.00 to $43.00 and gave the stock a “buy” rating in a research report on Thursday, March 19th. Wells Fargo & Company reduced their price target on Heartflow from $38.00 to $35.00 and set an “overweight” rating on the stock in a research note on Thursday, March 19th. JPMorgan Chase & Co. lowered their price objective on Heartflow from $40.00 to $35.00 and set an “overweight” rating for the company in a research report on Thursday, March 19th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Heartflow in a research note on Monday, December 29th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.67.

Hedge Funds Weigh In On Heartflow

Large investors have recently bought and sold shares of the stock. Baillie Gifford & Co. purchased a new stake in shares of Heartflow during the 3rd quarter valued at $101,182,000. TD Asset Management Inc acquired a new position in Heartflow in the third quarter valued at $2,692,000. New York State Common Retirement Fund acquired a new position in Heartflow in the third quarter valued at $4,015,000. Fred Alger Management LLC purchased a new stake in Heartflow during the third quarter valued at about $9,997,000. Finally, JPMorgan Chase & Co. acquired a new stake in Heartflow during the third quarter worth about $13,887,000.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.